Topic: non-small cell lung cancer
NIH scientists have modeled the 3D structure of DHHC enzymes, which modify EGFRs, which are implicated in a range of cancers.
The study linked the drug to a 33% disease control rate in NSCLC patients who had previously progressed following treatment with an EGFR inhibitor.
Array and Pfizer's initial focus is to test drug combos in a phase 1b trial in non-small cell lung cancer and pancreatic cancer.
The deal will see Thermo Fisher validate and seek approval for a test to identify RET fusions in non-small cell lung cancer patients.
The TRK TKI achieved a median duration of response of 28.6 months, suggesting its effect may last longer than that of the incumbent.
The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.
The ALK inhibitor triggered responses in a significant minority of heavily pretreated patients, suggesting it can play a role in NSCLC treatment.
Incyte and Bristol-Myers Squibb/Flexus are set to go to war in the courts over claims that a former scientist stole info around an oncology med.
Two commonly mutated genes in lung cancer may make some tumor cells especially vulnerable to an experimental drug from Calithera Biosciences.
The deal sees CRUK take a stake in the biotech in return for help testing a 5T4-CD3 bispecific antibody in patients with solid tumors.